NO20041266L - Piperidinderivater som kan anvendes som CCR5-antagonister - Google Patents

Piperidinderivater som kan anvendes som CCR5-antagonister

Info

Publication number
NO20041266L
NO20041266L NO20041266A NO20041266A NO20041266L NO 20041266 L NO20041266 L NO 20041266L NO 20041266 A NO20041266 A NO 20041266A NO 20041266 A NO20041266 A NO 20041266A NO 20041266 L NO20041266 L NO 20041266L
Authority
NO
Norway
Prior art keywords
piperidine derivatives
ccr5 antagonists
ccr5
antagonists
piperidine
Prior art date
Application number
NO20041266A
Other languages
English (en)
Inventor
Michael W Miller
Anandan Palani
Jack D Scott
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20041266L publication Critical patent/NO20041266L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20041266A 2001-08-29 2004-03-26 Piperidinderivater som kan anvendes som CCR5-antagonister NO20041266L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31568301P 2001-08-29 2001-08-29
PCT/US2002/027389 WO2003020716A1 (en) 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
NO20041266L true NO20041266L (no) 2004-03-26

Family

ID=23225580

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041266A NO20041266L (no) 2001-08-29 2004-03-26 Piperidinderivater som kan anvendes som CCR5-antagonister

Country Status (24)

Country Link
US (4) US20040010008A1 (no)
EP (1) EP1421075B1 (no)
JP (2) JP4223950B2 (no)
KR (1) KR20040029057A (no)
CN (1) CN1304389C (no)
AR (1) AR036366A1 (no)
AT (1) ATE328879T1 (no)
BR (1) BR0212108A (no)
CA (1) CA2457861A1 (no)
CY (1) CY1105198T1 (no)
DE (1) DE60212146T2 (no)
DK (1) DK1421075T3 (no)
EC (1) ECSP044993A (no)
ES (1) ES2264491T3 (no)
HK (1) HK1061563A1 (no)
HU (1) HUP0402019A3 (no)
IL (1) IL160060A0 (no)
MX (1) MXPA04001886A (no)
NO (1) NO20041266L (no)
PL (1) PL368827A1 (no)
PT (1) PT1421075E (no)
RU (1) RU2004109510A (no)
WO (1) WO2003020716A1 (no)
ZA (1) ZA200401594B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
ES2258642T3 (es) 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
US20040082612A1 (en) * 2002-10-15 2004-04-29 Baxter Ellen W Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
JP4757802B2 (ja) 2003-11-03 2011-08-24 シェーリング コーポレイション ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
JP2007513082A (ja) * 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071958A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008528477A (ja) * 2005-01-20 2008-07-31 ファイザー・リミテッド 化合物
AR055313A1 (es) * 2005-02-23 2007-08-15 Schering Corp Derivados piperidinil piperidina utiles como inhibidores de receptores de quimioquinas. proceso de obtencion y composiciones farmaceuticas
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2009043747A2 (en) * 2007-10-01 2009-04-09 F. Hoffmann-La Roche Ag N-heterocyclic biaryl carboxamides as ccr receptor antagonists
WO2009153182A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
AP2016009303A0 (en) 2013-12-19 2016-06-30 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines
WO2015091420A1 (de) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
JP2017503783A (ja) 2013-12-19 2017-02-02 バイエル ファーマ アクチエンゲゼルシャフト アドレナリン受容体アルファ２ｃ拮抗薬としての置換されたビピペリジニル誘導体
DK3277284T3 (da) 2015-04-02 2020-10-26 Proximagen Llc Hidtil ukendte terapier mod kræft
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0912515B1 (en) * 1996-07-10 2002-11-13 Schering Corporation 1,4-di-substituted piperidines as muscarinic antagonists
ATE299866T1 (de) * 1999-05-04 2005-08-15 Schering Corp Piperidinderivate verwendbar als ccr5 antagonisten
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
JP2008222722A (ja) 2008-09-25
IL160060A0 (en) 2004-06-20
HUP0402019A2 (hu) 2005-02-28
US7442703B2 (en) 2008-10-28
PL368827A1 (en) 2005-04-04
EP1421075A1 (en) 2004-05-26
CN1551877A (zh) 2004-12-01
US20040092551A1 (en) 2004-05-13
KR20040029057A (ko) 2004-04-03
WO2003020716A1 (en) 2003-03-13
CA2457861A1 (en) 2003-03-13
DE60212146D1 (de) 2006-07-20
US8034933B2 (en) 2011-10-11
CY1105198T1 (el) 2010-03-03
ECSP044993A (es) 2004-04-28
EP1421075B1 (en) 2006-06-07
JP2005502682A (ja) 2005-01-27
HK1061563A1 (en) 2004-09-24
BR0212108A (pt) 2004-08-24
US7384948B2 (en) 2008-06-10
MXPA04001886A (es) 2004-06-15
US20040092745A1 (en) 2004-05-13
JP4223950B2 (ja) 2009-02-12
ATE328879T1 (de) 2006-06-15
DK1421075T3 (da) 2006-09-18
US20080214575A1 (en) 2008-09-04
ZA200401594B (en) 2004-11-24
ES2264491T3 (es) 2007-01-01
RU2004109510A (ru) 2005-10-20
DE60212146T2 (de) 2007-06-06
PT1421075E (pt) 2006-10-31
AR036366A1 (es) 2004-09-01
HUP0402019A3 (en) 2009-07-28
CN1304389C (zh) 2007-03-14
US20040010008A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
NO20041266L (no) Piperidinderivater som kan anvendes som CCR5-antagonister
NO20040028L (no) Substituerte anilinske piperidiner som MCH-selektive antagonister
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20015366L (no) Piperazinderivater som er anvendbare som CCR5-antagonister
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DK1492786T3 (da) Pyridinoylpiperidiner som 5-HT1F-agonister
DK1515969T3 (da) Spiroindolinpiperidinderivater
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
NO20021450D0 (no) Cykliske aminforbindelser som CCR5 antagonister
NO20021239L (no) Pteridinoner som kinase-inhibitorer
IS7453A (is) Trópan afleiður sem CCR5 stillar
ATE308543T1 (de) Piperidinderivate
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
NO20034695D0 (no) Nye sammensetninger
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
DK1641784T3 (da) 4-(aminomethyl)piperidinbenzamider som 5HT - antagonister
NO20032315L (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
NO20043119L (no) Triazolokinolinderivater som kan anvendes som adenosinreseptorligander
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine
NO20053598D0 (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application